Metaxalone

Identification

Name
Metaxalone
Accession Number
DB00660  (APRD00514)
Type
Small Molecule
Groups
Approved
Description

Metaxalone (marketed by King Pharmaceuticals under the brand name Skelaxin®) is a muscle relaxant used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions. Its exact mechanism of action is not known, but it may be due to general central nervous system depression. It is considered to be a moderately strong muscle relaxant, with relatively low incidence of side effects. Skelaxin comes in an 800 mg scored tablet. It previously came in both 400 mg and 800 mg tablets. The 400 mg tablet has been discontinued. Possible side effects include nausea, vomiting, drowsiness and CNS side effects such as dizziness, headache, and irritability.

Structure
Thumb
Synonyms
  • Metassalone
  • Metaxalon
  • Metaxalona
  • Metaxalonum
External IDs
AHR 438
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetaxaloneTablet800 mg/1OralA S Medication Solutions2007-11-012017-06-20Us
MetaxaloneTablet800 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2011-12-06Not applicableUs
MetaxaloneTablet800 mg/1OralCarilion Materials Management2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralH.J. Harkins Company2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralUnit Dose Services2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralPreferreed Pharmaceuticals Inc.2014-02-14Not applicableUs
MetaxaloneTablet800 mg/1OralPd Rx Pharmaceuticals, Inc.2007-11-01Not applicableUs64720 0321 10 nlmimage10 6108b0b5
MetaxaloneTablet800 mg/1OralStat Rx USA2007-11-012018-02-08Us
MetaxaloneTablet800 mg/1Oralbryant ranch prepack2007-11-012018-05-31Us
MetaxaloneTablet800 mg/1OralNorthwind Pharmaceuticals2014-04-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetaxallTablet800 mg/1OralSircle Laboratories, Llc2015-09-25Not applicableUs
MetaxaloneTablet800 mg/1OralBlue Point Laboratories2014-04-22Not applicableUs
MetaxaloneTablet800 mg/1OralBlenheim Pharmacal, Inc.2013-09-11Not applicableUs
MetaxaloneTablet800 mg/1OralA S Medication Solutions2013-05-312017-06-20Us
MetaxaloneTablet800 mg/1OralAidarex Pharmaceuticals LLC2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralSt. Marys Medical Park Pharmacy2017-06-19Not applicableUs
MetaxaloneTablet800 mg/1OralKeltman Pharmaceuticals Inc.2008-06-25Not applicableUs
MetaxaloneTablet800 mg/1OralAmneal Pharmaceuticals2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralRed Pharm Drug, Inc.2010-03-31Not applicableUs
MetaxaloneTablet800 mg/1OralGemini Pharmaceuticals, Inc.2015-12-302017-12-22Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Lorvatus PharmaPakMetaxalone (800 mg/1) + Diclofenac sodium (16.05 mg/1mL) + Isopropyl Alcohol (0.7 mL/1mL)KitSircle Laboratories, Llc2015-12-012018-01-16Us
International/Other Brands
Skelaxin
Categories
UNII
1NMA9J598Y
CAS number
1665-48-1
Weight
Average: 221.2524
Monoisotopic: 221.105193351
Chemical Formula
C12H15NO3
InChI Key
IMWZZHHPURKASS-UHFFFAOYSA-N
InChI
InChI=1S/C12H15NO3/c1-8-3-9(2)5-10(4-8)15-7-11-6-13-12(14)16-11/h3-5,11H,6-7H2,1-2H3,(H,13,14)
IUPAC Name
5-(3,5-dimethylphenoxymethyl)-1,3-oxazolidin-2-one
SMILES
CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1

Pharmacology

Indication

For the treatment of painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes.

Associated Conditions
Pharmacodynamics

Metaxalone is a skeletal muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.

Mechanism of action

The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression.

Absorption

The absolute bioavailability of metaxalone from Skelaxin tablets is not known.

Volume of distribution
  • 800 L
Protein binding
Not Available
Metabolism

Probably hepatic.

Route of elimination

Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.

Half life

9.2 (+/- 4.8) hours

Clearance
  • 68 +/- 50 L/h [Subjects received 1×400mg tablet under fasted conditions]
  • 66 +/- 51 L/h [Subjects received 2×400 mg tablets under fasted conditions]
Toxicity

LD50=775mg/kg (Rat, oral); LD50=1690 mg/kg (Mouse, oral). When determining the LD50 in rats and mice, progressive sedation, hypnosis and finally respiratoryfailure were noted as the dosage increased. In dogs, no LD50 could be determined as the higher doses produced an emetic action in 15 to 30 minutes.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Metaxalone is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Metaxalone is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Metaxalone.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Metaxalone.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Metaxalone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Metaxalone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Metaxalone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Metaxalone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Metaxalone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Azaperone.Investigational, Vet Approved
AzelastineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Metaxalone.Approved
BarbitalThe risk or severity of adverse effects can be increased when Metaxalone is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Metaxalone is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Metaxalone.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Metaxalone is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Bupivacaine.Approved, Investigational
BuprenorphineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Metaxalone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Metaxalone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Metaxalone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Metaxalone is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Metaxalone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Metaxalone.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Metaxalone is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Metaxalone.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Metaxalone is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Metaxalone.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Metaxalone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Metaxalone.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Metaxalone.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Metaxalone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Metaxalone is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Metaxalone.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Metaxalone.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Metaxalone is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Metaxalone.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Metaxalone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Metaxalone.Approved
CocaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Metaxalone.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metaxalone.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Metaxalone.Approved
DantroleneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Metaxalone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metaxalone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Metaxalone.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Metaxalone is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metaxalone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Metaxalone.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metaxalone.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Doxepin.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Metaxalone is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Metaxalone.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Metaxalone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Metaxalone is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Metaxalone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Metaxalone.Approved, Investigational
EthanolMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Metaxalone.Approved
EthotoinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metaxalone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Metaxalone.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Metaxalone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Metaxalone.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Metaxalone.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Metaxalone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Metaxalone is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Metaxalone.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Metaxalone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Metaxalone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Metaxalone is combined with Hexobarbital.Approved
HydrocodoneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Metaxalone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Metaxalone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Metaxalone is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Metaxalone.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Metaxalone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Metaxalone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Metaxalone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Metaxalone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Metaxalone is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Metaxalone can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Metaxalone.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Metaxalone.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Lormetazepam.Approved
LorpiprazoleThe therapeutic efficacy of Metaxalone can be increased when used in combination with Lorpiprazole.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Metaxalone.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Metaxalone.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Metaxalone can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Metaxalone is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Metaxalone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Metaxalone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Mesoridazine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metaxalone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Metaxalone.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Metaxalone.Approved
MethotrimeprazineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methylphenobarbital.Approved
MetyrosineMetaxalone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Metaxalone.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Metaxalone is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Investigational
MirtazapineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Metaxalone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Metaxalone.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Metaxalone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Metaxalone.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Metaxalone.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Metaxalone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Metaxalone is combined with Opium.Approved, Illicit
OrphenadrineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Metaxalone is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Metaxalone.Approved
OxprenololThe risk or severity of adverse effects can be increased when Metaxalone is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metaxalone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Metaxalone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Metaxalone.Approved
ParaldehydeMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metaxalone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Metaxalone.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
PerazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Metaxalone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Metaxalone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Metaxalone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Metaxalone is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Metaxalone.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Metaxalone.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Metaxalone.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pomalidomide.Approved
PramipexoleMetaxalone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Metaxalone can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metaxalone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Metaxalone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Metaxalone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Metaxalone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Metaxalone.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Metaxalone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Metaxalone is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Metaxalone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Metaxalone.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metaxalone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Metaxalone.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Metaxalone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Romifidine.Vet Approved
RopiniroleMetaxalone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ropivacaine.Approved
RotigotineMetaxalone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Metaxalone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Metaxalone.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Metaxalone is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Metaxalone.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metaxalone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Sultopride.Experimental
SuvorexantMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tasimelteon.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Metaxalone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tetrodotoxin.Investigational
ThalidomideMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Metaxalone is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Metaxalone is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Metaxalone.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Metaxalone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tizanidine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metaxalone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Metaxalone.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Metaxalone.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Metaxalone.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Metaxalone.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Metaxalone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Metaxalone is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Metaxalone is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Metaxalone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Metaxalone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Metaxalone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zolazepam.Vet Approved
ZolpidemMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Metaxalone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Metaxalone.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Spiridon Spireas, "Bioavailable compositions of metaxalone and processes for producing the same." U.S. Patent US20050276844, issued December 15, 2005.

US20050276844
General References
  1. See S, Ginzburg R: Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70. [PubMed:18711953]
  2. Elenbaas JK: Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980 Oct;37(10):1313-23. [PubMed:6999895]
External Links
Human Metabolome Database
HMDB0014798
KEGG Drug
D00773
KEGG Compound
C07934
PubChem Compound
15459
PubChem Substance
46506253
ChemSpider
14709
ChEBI
6797
ChEMBL
CHEMBL1079604
PharmGKB
PA164747189
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Metaxalone
FDA label
Download (124 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentLow Back Pain (LBP)1

Pharmacoeconomics

Manufacturers
  • Sandoz inc
  • King pharmaceuticals inc
  • Elan Corporation
Packagers
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Blenheim Pharmacal
  • Cardinal Health
  • D.M. Graham Laboratories Inc.
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • H.J. Harkins Co. Inc.
  • Innoviant Pharmacy Inc.
  • Keltman Pharmaceuticals Inc.
  • King Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Mckesson Corp.
  • Nucare Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prescript Pharmaceuticals
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Resource Optimization and Innovation LLC
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
Kit
TabletOral400 mg/1
TabletOral800 mg/1
Prices
Unit descriptionCostUnit
Metaxalone 800 mg tablet3.88USD tablet
Skelaxin 800 mg tablet3.84USD tablet
Skelaxin 400 mg tablet0.84USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6407128No2001-12-032021-12-03Us
US7122566No2006-02-062026-02-06Us
US7714006No2001-12-032021-12-03Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)122 °CPhysProp
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.28 mg/mLALOGPS
logP1.63ALOGPS
logP2.37ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)13.14ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area47.56 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity59.32 m3·mol-1ChemAxon
Polarizability23.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9747
Caco-2 permeable+0.5076
P-glycoprotein substrateNon-substrate0.7072
P-glycoprotein inhibitor INon-inhibitor0.8309
P-glycoprotein inhibitor IINon-inhibitor0.906
Renal organic cation transporterNon-inhibitor0.8464
CYP450 2C9 substrateNon-substrate0.8154
CYP450 2D6 substrateNon-substrate0.7182
CYP450 3A4 substrateNon-substrate0.5649
CYP450 1A2 substrateInhibitor0.6863
CYP450 2C9 inhibitorNon-inhibitor0.7448
CYP450 2D6 inhibitorNon-inhibitor0.7733
CYP450 2C19 inhibitorNon-inhibitor0.6471
CYP450 3A4 inhibitorNon-inhibitor0.911
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.797
Ames testNon AMES toxic0.6074
CarcinogenicityNon-carcinogens0.9312
BiodegradationNot ready biodegradable0.9544
Rat acute toxicity2.4250 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9319
hERG inhibition (predictor II)Non-inhibitor0.913
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0490000000-964e6b5348bafc1182d9
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0089-0980000000-2b6e14f3b5e5c19c4e5c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0910000000-c8b21539b07eb2e7d34e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0900000000-0f09eb181838526daa7c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0900000000-018693fc5b6345ee25c5
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0900000000-921f9f6e188e7466aa4d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-08fr-4900000000-222616eabf1bcdd48049
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-08fr-6900000000-06981ad91bcbeda7d385
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-6900000000-77e22c24cb4c6bbc81a1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-8900000000-54c62bf2b5c1b70898bb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9700000000-82878fa5fbb78b27ef0b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9500000000-66f674cba4e44834a425

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
m-Xylenes / Phenoxy compounds / Alkyl aryl ethers / Oxazolines / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
Phenoxy compound / M-xylene / Xylene / Phenol ether / Alkyl aryl ether / Monocyclic benzene moiety / Oxazoline / Ether / Propargyl-type 1,3-dipolar organic compound / Organic 1,3-dipolar compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
aromatic ether (CHEBI:6797)

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 06:38